Piramal Enterprises Share PricePiramal Enterprises

6 (0.76%)
As on 07 June, 2023 | 16:56 BSE: 500302 NSE: PEL

Piramal Enterprises Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Piramal Enterprises

Start SIP

Piramal Enterprises Share Price

  • Over 1 Month 7.99%
  • Over 3 Month 1.71%
  • Over 6 Month -11.92%
  • Over 1 Year -55.8%

Piramal Enterprises Key Statistics

P/E Ratio 8.2
PEG Ratio 0.4
Market Cap Cr 18,940
Price to Book Ratio 0.6
EPS 101.4
Dividend 4.2
Relative Strength Index 67.18
Money Flow Index 65.78
MACD Signal 13.21
Average True Range 16.78

Piramal Enterprises Investment Rating

  • Master Rating:
  • Piramal Enterprises has an operating revenue of Rs. 10,805.43 Cr. on a trailing 12-month basis. An annual revenue de-growth of -38% needs improvement, Pre-tax margin of 13% is healthy, ROE of 32% is exceptional. The company has a high debt to equity of 123%, which can be a reason to worry. The stock from a technical standpoint is trading below to its 200DMA and around 8% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 110 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Piramal Enterprises Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1813,763455513574
Operating Expenses Qtr Cr 31650971357341
Operating Profit Qtr Cr 1503,113-516151232
Depreciation Qtr Cr 28766
Interest Qtr Cr 167165150156168
Tax Qtr Cr 4658-150444
Net Profit Qtr Cr -572,892-5128316

Piramal Enterprises Technicals


Current Price
6 (0.76%)
  • Bullish Moving Average
  • ___
  • 14
  • Bearish Moving Average
  • ___
  • 2
  • 20 Day
  • ₹765.44
  • 50 Day
  • ₹753
  • 100 Day
  • ₹789.48
  • 200 Day
  • ₹969.09
  • 20 Day
  • ₹761.87
  • 50 Day
  • ₹727.51
  • 100 Day
  • ₹766.66
  • 200 Day
  • ₹873.11

Piramal Enterprises Resistance and Support

First Resistance ₹796.75
Second Resistance ₹805.9
Third Resistance ₹814.1
RSI 67.19
MFI 65.78
MACD Single Line 13.21
MACD 14.81
First Resistance ₹779.4
Second Resistance ₹771.2
Third Resistance ₹762.05

Piramal Enterprises Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 710,716 19,168,011 26.97
Week 847,292 32,841,030 38.76
1 Month 990,068 36,612,703 36.98
6 Month 1,179,366 38,753,958 32.86

Piramal Enterprises Result Highlights

Piramal Enterprises Synopsis


Piramal Enterprises is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4785.22 Cr. and Equity Capital is Rs. 47.73 Cr. for the Year ended 31/03/2023. Piramal Enterprises Ltd. is a Public Limited Listed company incorporated on 26/04/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1947PLC005719 and registration number is 005719.
Market Cap 18,816
Sales 4,912
Shares in Float 13.60
No of funds 278
Yield 3.94
Book Value 0.78
U/D Vol ratio 1.2
LTDebt / Equity 16
Alpha -0.13
Beta 1.55

Piramal Enterprises

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 43.48%43.48%43.48%43.49%
Mutual Funds 4.25%2.07%1.89%2.02%
Insurance Companies 5.25%5.27%5.28%6.03%
Foreign Portfolio Investors 28.67%31.25%32.05%34.54%
Financial Institutions/ Banks 0.01%
Individual Investors 13.17%12.33%11.71%9.29%
Others 5.18%5.59%5.59%4.63%

Piramal Enterprises Management

Name Designation
Mr. Ajay G Piramal Chairman
Dr.(Mrs.) Swati A Piramal Vice Chairperson
Ms. Nandini Piramal Executive Director
Mr. Puneet Dalmia Independent Director
Mr. Anand Piramal Non Executive Director
Mr. Vijay Shah Non Executive Director
Mr. Kunal Bahl Independent Director
Mr. Khushru Jijina Executive Director
Ms. Anjali Bansal Independent Director
Mr. S Ramadorai Independent Director
Mr. Shikha Sharma Independent Director
Mr. N Vaghul Independent Director
Mr. Suhail Nathani Independent Director
Mr. Anita George Independent Director
Mr. Rajiv Mehrishi Independent Director

Piramal Enterprises Forecast

Price Estimates


Other Analyst Rating

Piramal Enterprises Corporate Action

Date Purpose Remarks
2023-05-05 Audited Results & Final Dividend
2023-02-08 Quarterly Results
2022-11-09 Quarterly Results
2022-07-29 Quarterly Results
2022-07-14 To consider raising of funds
Date Purpose Remarks
2023-06-16 FINAL Rs.31.00 per share(1550%)Final Dividend
2022-07-15 FINAL Rs.33.00 per share(1650%)Final Dividend
2021-07-07 FINAL Rs.33.00 per share(1650%)Final Dividend

Piramal Enterprises MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 54413
Kotak Equity Arbitrage Fund Growth 20587
Nippon India Growth Fund - Growth 14143
Nippon India Tax Saver (ELSS) Fund - Growth 11451
ICICI Prudential Equity Arbitrage Fund Regular Growth 10189

About Company

Piramal Enterprises Limited is an Indian multinational pharmaceutical and financial services company based in Mumbai, Maharashtra. Founded by Ajay Piramal (who is also the Chairman), the company operates in the pharmaceuticals, financial services and real estate sector.

He founded the company in 1984 after he acquired a small-scale manufacturing unit from his father. Today, Piramal has more than 50 offices across 30 countries and employs over 10,000 people worldwide. With a presence in 100+ countries through its subsidiaries or associate companies. Piramal has been ranked among Forbes Asia’s 200 Best Under A Billion in 2019.

Business Verticals

PEL's Global Pharma division has a strong product portfolio of niche differentiated branded generics that are difficult to manufacture, sell, or distribute. Through its worldwide network of facilities, PEL's Contract Development and Manufacturing Organisation (CDMO) services segment provide end-to-end solutions across the drug life cycle. 

The Indian consumer products division of PEL serves India’s self-care market. PEL's OTC portfolio includes 21 major pharmaceutical and personal care brands in diverse product categories such as Vitamins & Nutrition, Dermatological & Antacids, Analgesics, and Baby Care. PEL's Healthcare Insights & Analytics division is the world's leading provider of healthcare analytics data, insight products and services to the world's leading pharma, biotech and medical technology companies, allowing them to make informed business decisions.

PEL's financial services include wholesale lending, housing finance, and alternative asset management. Piramal Capital & Housing Finance Ltd, PEL's wholly-owned subsidiary, is registered as a housing finance company with National Housing Bank (NHB) and is involved in a variety of financial services businesses. It offers wholesale and retail funding opportunities across industries.

Company History

Piramal Enterprises was founded as Indian Schering Limited on April 26, 1947, by British Schering Ltd. With effect from September 27, 1979, the company's name was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd. Gujarat Glass Ltd (GGL) was acquired with the company on April 1, 1990. The new formulation plant in Pithampur, Madhya Pradesh, was inaugurated in 1991. After a year, in 1992, the company established a second formulation plant in Pithampur, Madhya Pradesh, with cutting-edge manufacturing facilities. The company's name changed from 'Nicholas Laboratories Ltd' to 'Nicholas Piramal India Ltd' on December 2, 1992.


Entered the pharmaceutical industry with the purchase of Nicholas Laboratories.
A series of mergers and acquisitions, joint ventures and alliances, and organic initiatives.

Over two decades, they built a leading Indian pharmaceutical company.
The Domestic Formulations business was sold to Abbott in 2010 for USD 3.8 billion. Diagnostic Services were sold to Super Religare Laboratories.

From 2020 onwards
Multiple capital raise initiatives helped to strengthen the balance sheet.
Through the sale of DRG and the exit of Shriram Transport, the organization structure was simplified.
Subsidized the pharmaceutical businesses and raised new capital from Carlyle Transforming Financial Services with the DHFL acquisition to deliver long-term growth and profitability.

Piramal Enterprises FAQs

What is Share Price of Piramal Enterprises ?

Piramal Enterprises share price is ₹793 As on 07 June, 2023 | 16:42

What is the Market Cap of Piramal Enterprises ?

The Market Cap of Piramal Enterprises is ₹18940.4 Cr As on 07 June, 2023 | 16:42

What is the P/E ratio of Piramal Enterprises ?

The P/E ratio of Piramal Enterprises is 8.2 As on 07 June, 2023 | 16:42

What is the PB ratio of Piramal Enterprises ?

The PB ratio of Piramal Enterprises is 0.6 As on 07 June, 2023 | 16:42

What were the company's most recent reported sales and net income?

Piramal Enterprises Ltd recorded net sales of INR 13993 crores in the year ending March 2022. 

What is the future of the company's shares?

Piramal Enterprises Ltd stock may be a good buy according to market analysts considering meaningful inroads into Retail led by mortgages and small-term loans via digital alliance.

How to buy shares of Piramal Enterprises Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.


Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number